PMID- 2838924
OWN - NLM
STAT- MEDLINE
DCOM- 19880729
LR  - 20041117
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 59
IP  - 2
DP  - 1988 Apr 8
TI  - Low molecular weight heparin in haemodialysis for chronic renal failure: dose 
      finding study of CY222.
PG  - 240-7
AB  - A dose finding study of the very low molecular weight heparin CY222 (MW 2500) in 
      patients (n = 8) with chronic renal failure undergoing dialysis has been carried 
      out to (i) establish an effective dose and (ii) determine the relationship 
      between ex vivo anti-factor Xa levels in plasma and the anticoagulant effect (in 
      vivo suppression of FPA levels). Doses of CY222 were compared to a dose (5000 iu 
      bolus + 1500 iu/hr) of unfractionated heparin (UFH) that has been shown to 
      suppress FPA levels during prolonged (greater than 5 hr) dialysis (Ireland et 
      al., J Lab Clin Med 103, 643, 1984). CY222 given iv in increasing doses produced 
      a dose related increase in anti-factor Xa levels (measured as Institute Choay 
      u/ml, with CY222 itself as standard) and suppression of FPA levels. When given in 
      its highest dose, 20,000 Institute Choay u bolus + 1500 Institute Choay u/hr, 
      there was little effect upon KCCT, FPA levels were statistically 
      indistinguishable from those of the UFH regime (indicating comparable 
      anticoagulant effect), but anti-factor Xa levels (expressed in Institute Choay 
      u/ml) were 2-3 times those of UFH (expressed in iu/ml). All samples were also 
      assayed for anti-factor Xa level against the proposed low MW Heparin Standard. 
      Plasma levels of CY222 were then found to be 2.78 times lower, so that the 
      anti-factor Xa levels of CY222 required to produce comparable anticoagulant 
      effect were then indistinguishable from those of UFH.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Ireland, H
AU  - Ireland H
AD  - Department of Haematology, Charing Cross and Westminster Hospital, London, UK.
FAU - Lane, D A
AU  - Lane DA
FAU - Flynn, A
AU  - Flynn A
FAU - Pegrum, A C
AU  - Pegrum AC
FAU - Curtis, J R
AU  - Curtis JR
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 0 (beta-Thromboglobulin)
RN  - 25422-31-5 (Fibrinopeptide A)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Drug Evaluation
MH  - Factor Xa
MH  - Fibrinopeptide A/metabolism
MH  - Heparin/administration & dosage
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Humans
MH  - Kidney Failure, Chronic/blood/drug therapy/*therapy
MH  - *Renal Dialysis
MH  - Serine Proteinase Inhibitors
MH  - beta-Thromboglobulin/metabolism
EDAT- 1988/04/08 00:00
MHDA- 1988/04/08 00:01
CRDT- 1988/04/08 00:00
PHST- 1988/04/08 00:00 [pubmed]
PHST- 1988/04/08 00:01 [medline]
PHST- 1988/04/08 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1988 Apr 8;59(2):240-7.